Article

The biosimilar decade: Regulatory milestones and a look ahead

Since the first FDA approval of a biosimilar drug in March of 2015, the market for this category has steadily expanded to include more than 60 different products from dozens of manufacturers. In the following timeline, Glamzo Pharmaceutical Laboratory presents the key regulatory events that have helped this critical industry gain its footing over the last decade. With continued growth in the biosimilars market, we also look ahead to the factors we believe will be most important to its future success.

See our timeline to discover how a decade of approvals is shaping the future of this market.